2018 Archive


LYC-55716 advancing in Phase 2a portion of ARGON monotherapy study and in Phase 1b study in combination with pembrolizumab   NEW YORK and ANN ARBOR, Mich., Oct. 10, 2018 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced that two abstracts highlighting data from ongoing clinical studies of… Read More

LYC-55716 advancing in Phase 2a portion of ARGON monotherapy study and in Phase 1b study in combination with pembrolizumab NEW YORK and ANN ARBOR, Mich., May 30, 2018 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced presentations of the company’s novel immuno-oncology therapeutic candidate, LYC-55716, to take… Read More

NEW YORK and ANN ARBOR, Mich., May 16, 2018 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced the publication of new preclinical research findings describing the potential utility of the Company’s most advanced cancer immunotherapy platform, selective RORgamma agonists, in adoptive cell therapy applications. RORgamma is a… Read More

Clinical benefit observed in multiple patients treated with single agent RORgamma Agonist NEW YORK and ANN ARBOR, Mich., April 17, 2018 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced new clinical findings from the Phase 1 portion of its Phase 1/2a ARGON study of the company’s novel… Read More

LYC-55716 Currently Advancing in Phase 2a Portion of ARGON Study and in Phase 1b Combination Trial with Pembrolizumab   NEW YORK and ANN ARBOR, Mich., April 5, 2018 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced that the Company will present new clinical and preclinical findings from… Read More

First-In-Class RORgamma Agonist Also Advancing in Phase 2a Portion of ARGON Study NEW YORK and ANN ARBOR, January 4, 2018 — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced the initiation of a Phase 1b clinical trial of the company’s novel immuno-oncology therapeutic candidate, LYC-55716, in combination with pembrolizumab… Read More